Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.
Gastroenterology
; 155(2): 479-489.e7, 2018 08.
Article
in En
| MEDLINE
| ID: mdl-29655834
Full text:
1
Collection:
01-internacional
Health context:
6_ODS3_enfermedades_notrasmisibles
Database:
MEDLINE
Main subject:
Pancreatic Neoplasms
/
Somatostatin
/
Neuroendocrine Tumors
/
Diabetes Mellitus, Type 2
/
Everolimus
/
Metformin
/
Antineoplastic Agents
Type of study:
Observational_studies
/
Risk_factors_studies
Limits:
Adolescent
/
Adult
/
Aged
/
Aged80
/
Child
/
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
Europa
Language:
En
Journal:
Gastroenterology
Year:
2018
Document type:
Article